Axelsson-Robertson Rebecca, Ahmed Raija K, Weichold Frank F, Ehlers Marthie M, Kock Marleen M, Sizemore Donata, Sadoff Jerry, Maeurer Markus
Department of Microbiology and Tumor Cell Biology, Karolinska Institutet, Nobels Väg 18, Stockholm SE-171 82, Sweden.
Clin Vaccine Immunol. 2011 Jan;18(1):125-34. doi: 10.1128/CVI.00302-10. Epub 2010 Nov 17.
High-tuberculosis (TB)-burden countries are located in sub-Saharan Africa. We examined the frequency of human leukocyte antigen (HLA) alleles, followed by recombinant expression of the most frequent HLA-A alleles, i.e., HLA-A3001 and HLA-A3002, to study differences in mycobacterial peptide presentation and CD8(+) T-cell recognition. We screened a peptide library (9-mer peptides with an 8-amino-acid overlap) for binding, affinity, and off-rate of the Mycobacterium tuberculosis-associated antigen TB10.4 and identified only three TB10.4 peptides with considerable binding to HLA-A3001. In contrast, 22 peptides bound to HLA-A3002. This reflects a marked difference in the binding preference between the two alleles, with A3002 tolerating a more promiscuous peptide-binding pattern and A3001 accommodating only a very selective peptide repertoire. Subsequent analysis of the affinity and off-rate of the binding peptides revealed a strong affinity (8 nM to 7 μM) and moderate off-rate (20 min to 3 h) for both alleles. Construction of HLA-A3001 and HLA-A3002 tetramers containing selected binding peptides from TB10.4, including a peptide which was shared among both alleles, QIMYNYPAM (TB10.4(3-11)), allowed us to enumerate epitope-specific T cells in HLA-A3001- and HLA-A3002-typed patients with active TB. HLA-A3001 and HLA-A3002 major histocompatibility complex-peptide complexes were recognized in individuals with active TB, irrespective of their homozygous HLA-A3001 or HLA-A3002 genetic background. The antigen-specific T cells exhibited the CD45RA(+) CCR7(+) precursor phenotype and the interleukin-7 receptor (CD127), which were different from the phenotype and receptor exhibited by the parental CD8(+) T-cell population.
结核病高负担国家位于撒哈拉以南非洲地区。我们检测了人类白细胞抗原(HLA)等位基因的频率,随后对最常见的HLA - A等位基因,即HLA - A3001和HLA - A3002进行重组表达,以研究分枝杆菌肽呈递和CD8(+) T细胞识别方面的差异。我们筛选了一个肽库(具有8个氨基酸重叠的9聚体肽),以检测结核分枝杆菌相关抗原TB10.4的结合、亲和力和解离速率,结果仅鉴定出3种与HLA - A3001有显著结合的TB10.4肽。相比之下,有22种肽与HLA - A3002结合。这反映出这两个等位基因在结合偏好上存在显著差异,A3002能容忍更混杂的肽结合模式,而A3001只容纳非常有选择性的肽库。随后对结合肽的亲和力和解离速率分析显示,这两个等位基因的结合肽都具有较强的亲和力(8 nM至7 μM)和适中的解离速率(20分钟至3小时)。构建包含来自TB10.4的选定结合肽的HLA - A3001和HLA - A3002四聚体,其中包括两个等位基因共有的一个肽QIMYNYPAM(TB10.4(3 - 11)),这使我们能够在患有活动性结核病的HLA - A3001型和HLA - A3002型患者中枚举表位特异性T细胞。无论其HLA - A3001或HLA - A3002是纯合基因背景,活动性结核病患者体内的HLA - A3001和HLA - A3002主要组织相容性复合体 - 肽复合物都能被识别。抗原特异性T细胞表现出CD45RA(+) CCR7(+)前体表型和白细胞介素 - 7受体(CD127),这与亲代CD8(+) T细胞群体所表现出的表型和受体不同。